Flag of the European Union EU Clinical Trials Register Help

Clinical trials for III

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44351   clinical trials with a EudraCT protocol, of which   7378   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    7,971 result(s) found for: III. Displaying page 380 of 399.
    «« First « Previous 376  377  378  379  380  381  382  383  384  Next» Last»»
    EudraCT Number: 2012-002332-85 Sponsor Protocol Number: MK-3102-019 Start Date*: 2013-03-14
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase III, Multicenter, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of MK-3102 Versus Placebo in Subjects with Type 2 Diabetes Mellitus with Moderate or Severe Chronic Kidn...
    Medical condition: Type 2 Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    17.1 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) HU (Completed) PL (Completed) ES (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-000177-31 Sponsor Protocol Number: CAN-004AB Start Date*: 2012-10-18
    Sponsor Name:Prima BioMed Ltd
    Full Title: CANVAS: A Randomized Trial of Cvac (Autologous Dendritic Cells Pulsed with Recombinant Human Fusion Protein [Mucin 1-Glutathione S Transferase] Coupled to Oxidized Polymannose) as Maintenance Treat...
    Medical condition: Maintenance Treatment in [A] Patients with Epithelial Ovarian Cancer (EOC) in Complete Remission Following First-Line Chemotherapy and [B] Patients with EOC in Second Remission
    Disease: Version SOC Term Classification Code Term Level
    17.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: LT (Prematurely Ended) BG (Prematurely Ended) DE (Prematurely Ended) BE (Completed) LV (Prematurely Ended) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-000001-23 Sponsor Protocol Number: 14861B Start Date*: 2014-02-27
    Sponsor Name:H. Lundbeck A/S
    Full Title: An open-label extension study to evaluate the long-term safety and tolerability of Lu AE58054 as adjunctive treatment to donepezil in patients with mild-moderate Alzheimer's disease
    Medical condition: Alzheimer´s disease
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004852 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) DE (Completed) EE (Completed) IT (Completed) BE (Completed) LT (Completed) ES (Completed) DK (Completed) BG (Completed) PT (Completed) GB (Completed) HU (Completed) FI (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2009-012759-12 Sponsor Protocol Number: WA19926 Start Date*: 2009-10-14
    Sponsor Name:F. Hoffmann-La Roche Ltd.
    Full Title: A multi-center, randomized, double-blind, parallel group study of the safety, disease remission and prevention of structural joint damage during treatment with tocilizumab (TCZ), as a monotherapy a...
    Medical condition: Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    12.0 10039073 Rheumatoid arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) AT (Completed) DE (Completed) ES (Completed) FI (Completed) FR (Completed) PT (Completed) DK (Completed) IE (Completed) GR (Completed) SE (Completed) IT (Completed) HU (Completed) CZ (Completed)
    Trial results: Removed from public view
    EudraCT Number: 2010-020337-99 Sponsor Protocol Number: WA21092 Start Date*: 2011-10-20
    Sponsor Name:F.Hoffmann-La Roche
    Full Title: A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study To Evaluate The Efficacy And Safety Of Ocrelizumab In Comparison To Interferon Beta-1a (Rebif®) In Patients With Relapsing Multiple Sc...
    Medical condition: Relapsing Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) FR (Completed) CZ (Completed) LV (Completed) HU (Completed) FI (Completed) DE (Completed) BE (Completed) SK (Completed) AT (Completed) NL (Ongoing) LT (Completed) EE (Completed) PT (Completed) BG (Completed) ES (Ongoing) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-001881-40 Sponsor Protocol Number: BO40747 Start Date*: 2018-11-27
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A phase III, randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of Atezolizumab or placebo in combination with neoadjuvant doxorubicin + cyclophosphamid...
    Medical condition: Early Human epidermal growth factor receptor 2 (HER2)-positive breast cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) ES (Temporarily Halted) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2021-003903-16 Sponsor Protocol Number: LPS16676 Start Date*: 2022-02-14
    Sponsor Name:Sanofi-aventis Recherche & Développement
    Full Title: A Randomized, Double-Blind, Placebo controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients with Uncontrolled Moderate to Severe Asthma (ATLAS)
    Medical condition: Asthma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Trial now transitioned) IE (Trial now transitioned) BE (Trial now transitioned) SK (Trial now transitioned) HU (Trial now transitioned) BG (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-005450-60 Sponsor Protocol Number: C25003 Start Date*: 2013-02-09
    Sponsor Name:Millennium Pharmaceuticals, Inc
    Full Title: A Randomized, Open-label, Phase 3 Trial of A+AVD Versus ABVD as Frontline Therapy in Patients With Advanced Classical Hodgkin Lymphoma
    Medical condition: Advanced Classical Hodgkin Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10025319 Lymphomas Hodgkin's disease HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Trial now transitioned) HU (Trial now transitioned) GB (GB - no longer in EU/EEA) BE (Trial now transitioned) IT (Trial now transitioned) DK (Trial now transitioned) ES (Ongoing) FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-005076-26 Sponsor Protocol Number: SGNTV-001 Start Date*: 2019-04-16
    Sponsor Name:Seagen, Inc.
    Full Title: Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors
    Medical condition: Locally Advanced or Metastatic Disease in Solid Tumors
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029521 Non-small cell lung cancer stage IIIB PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029522 Non-small cell lung cancer stage IV PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059515 Non-small cell lung cancer metastatic PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066490 Progression of non-small cell lung cancer LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033599 Pancreatic adenocarcinoma metastatic LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033600 Pancreatic adenocarcinoma non-resectable LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10051971 Pancreatic adenocarcinoma LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059326 Pancreatic carcinoma stage IV PT
    25.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033610 Pancreatic carcinoma metastatic PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033609 Pancreatic carcinoma PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059333 Pancreatic carcinoma stage IVA LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059335 Pancreatic carcinoma stage IVB LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033604 Pancreatic cancer LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033605 Pancreatic cancer metastatic LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033606 Pancreatic cancer non-resectable LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061902 Pancreatic neoplasm PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10071536 Head and neck cancer stage IV PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10071537 Head and neck cancer stage III PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10071540 Head and neck cancer metastatic PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10010035 Colorectal cancer stage IV PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052358 Colorectal cancer metastatic PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052362 Metastatic colorectal cancer LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10010023 Colorectal neoplasms malignant HLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052360 Colorectal adenocarcinoma PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) GB (GB - no longer in EU/EEA) FR (Trial now transitioned) ES (Ongoing) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-003855-40 Sponsor Protocol Number: MOR208C115 Start Date*: 2022-03-09
    Sponsor Name:MorphoSys AG
    Full Title: A Phase 1b/2, Open-Label, Multicenter Study to Evaluate the Safety and Pharmacokinetics of a Modified Tafasitamab IV Dosing Regimen Combined with Lenalidomide (LEN) in Patients with Relapsed or Ref...
    Medical condition: Diffuse Large B-Cell Lymphoma (DLBCL)
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012818 Diffuse large B-cell lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) AT (Trial now transitioned) CZ (Trial now transitioned) IT (Trial now transitioned) PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-005760-57 Sponsor Protocol Number: CA42750 Start Date*: 2021-08-27
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF OBINUTUZUMAB IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
    Medical condition: Systemic Lupus Erythematosus (SLE)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10028395 - Musculoskeletal and connective tissue disorders 10042945 Systemic lupus erythematosus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) ES (Ongoing) PL (Trial now transitioned) IT (Trial now transitioned) CZ (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-001605-93 Sponsor Protocol Number: 3151-201-008 Start Date*: 2019-07-01
    Sponsor Name:AstraZeneca AB
    Full Title: A 54-Week Treatment, Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo and Active-Controlled, Parallel-Group Phase 2 Study to Assess the Efficacy and Safety of Brazikumab in Participants...
    Medical condition: Ulcerative Colitis
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004856 10045365 Ulcerative colitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) BE (Completed) FR (Completed) CZ (Prematurely Ended) ES (Prematurely Ended) BG (Prematurely Ended) AT (Prematurely Ended) HU (Prematurely Ended) IT (Prematurely Ended) RO (Completed)
    Trial results: View results
    EudraCT Number: 2020-000146-33 Sponsor Protocol Number: MITO33 Start Date*: 2020-10-09
    Sponsor Name:FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE
    Full Title: Randomized phase III trial on NIraparib-TSR-042 (dostarlimab) vs physician’s choice CHEmotherapy in recurrent, ovarian, fallopian tube or primary peritoneal cancer patients not candidate for platin...
    Medical condition: Recurrent ovarian, fallopian tube or primary peritoneal cancer.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061344 Peritoneal neoplasm PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066697 Ovarian cancer recurrent PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10016180 Fallopian tube cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Trial now transitioned) DE (Trial now transitioned) FR (Trial now transitioned) CZ (Trial now transitioned) GR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2021-001700-15 Sponsor Protocol Number: MK-7684A-004 Start Date*: 2021-10-14
    Sponsor Name:Merck Sharp & Dohme LLC
    Full Title: A Phase 2, Open-label Study to Evaluate the Safety and Efficacy of MK-7684A (MK-7684 [Vibostolimab] with MK-3475 [Pembrolizumab] Coformulation) in Participants with Relapsed or Refractory Hematolog...
    Medical condition: Relapsed/refractory hematological malignancies
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10066481 Hematological malignancy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) DK (Completed) FR (Completed) ES (Ongoing) PL (Completed) IT (Completed) HU (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-002480-22 Sponsor Protocol Number: TAK-935-3001 Start Date*: 2021-07-22
    Sponsor Name:Takeda Development Center Americas, Inc
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy, Safety, and Tolerability of Soticlestat as Adjunctive Therapy in Pediatric and Young Adul...
    Medical condition: Dravet Syndrome (DS)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10073682 Dravet syndrome LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA IT (Completed) FR (Completed) ES (Completed) LV (Completed) GR (Completed) NL (Completed) BE (Completed) PL (Completed) HU (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2016-001646-25 Sponsor Protocol Number: 201584 Start Date*: 2016-10-20
    Sponsor Name:ViiV Healthcare, S.L.
    Full Title: A Phase III, Randomized, Multicenter, Parallel-group, Open- Label Study Evaluating the Efficacy, Safety, and Tolerability of Long-Acting Intramuscular Cabotegravir and Rilpivirine for Maintenance o...
    Medical condition: Human Immunodeficiency Virus type 1 (HIV-1)
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004862 10003582 Asymptomatic human immunodeficiency virus type I infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) GB (GB - no longer in EU/EEA) DE (Completed) NL (Ongoing) IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-002328-18 Sponsor Protocol Number: BP40657 Start Date*: 2018-12-19
    Sponsor Name:F. Hoffman-La Roche Ltd.
    Full Title: A RANDOMIZED, MULTICENTER, PHASE Ib/III STUDY TO INVESTIGATE THE PHARMACOKINETICS, EFFICACY, AND SAFETY OF ATEZOLIZUMAB SUBCUTANEOUS COMPARED WITH ATEZOLIZUMAB INTRAVENOUS IN PATIENTS WITH PREVIOUS...
    Medical condition: Non-small cell lung cancer (NSCLC)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059514 Small cell lung cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed) PL (Completed) HU (Completed) GR (Completed) BG (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-005435-75 Sponsor Protocol Number: U1111-1261-1912 Start Date*: 2022-07-21
    Sponsor Name:NOVO NORDISK. S.P.A.
    Full Title: Efficacy and safety of cagrilintide s.c. 2.4 mg in combination with semaglutide s.c. 2.4 mg (CagriSema s.c. 2.4 mg/2.4 mg) once-weekly in participants with overweight or obesity
    Medical condition: Obesity, Overweight
    Disease: Version SOC Term Classification Code Term Level
    24.1 10027433 - Metabolism and nutrition disorders 10033307 Overweight PT
    20.0 10027433 - Metabolism and nutrition disorders 10029883 Obesity PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned) NL (Trial now transitioned) DK (Trial now transitioned) FI (Trial now transitioned) FR (Trial now transitioned) ES (Ongoing) PL (Trial now transitioned) BE (Trial now transitioned) BG (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-003417-19 Sponsor Protocol Number: BN42644 Start Date*: 2022-01-03
    Sponsor Name:F. HOFFMANN - LA ROCHE LTD.
    Full Title: A TWO-PART, SEAMLESS, MULTI-CENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS AND EFFICACY OF RO7204239 IN COMBI...
    Medical condition: Spinal Muscular Atrophy (SMA)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10079415 Spinal muscular atrophy type III LLT
    20.1 100000004850 10051203 Spinal muscular atrophy congenital LLT
    20.1 100000004850 10041583 Spinal muscular atrophy, unspecified LLT
    20.0 100000004850 10079413 Spinal muscular atrophy type I LLT
    20.0 100000004850 10079416 Spinal muscular atrophy type II LLT
    20.0 100000004850 10079417 Spinal muscular atrophy infantile onset LLT
    20.0 100000004850 10079419 Spinal muscular atrophy pre-symptomatic LLT
    20.0 100000004850 10079418 Spinal muscular atrophy later onset LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: IT (Trial now transitioned) PL (Trial now transitioned) DE (Trial now transitioned) BE (Trial now transitioned) NL (Trial now transitioned) ES (Ongoing) FR (Trial now transitioned) PT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-002549-39 Sponsor Protocol Number: Ponatinib-1501 Start Date*: 2020-12-07
    Sponsor Name:Takeda Development Center Americas, Inc.
    Full Title: A Pivotal Phase 1/2, Single-Arm, Open-label Study to Evaluate the Safety and Efficacy of Ponatinib With Chemotherapy in Pediatric Patients With Philadelphia Chromosome-Positive (Ph+) Acute Lympho...
    Medical condition: acute lymphoblastic leukemia
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10000845 Acute lymphoblastic leukemia LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) FR (Completed) CZ (Completed) NL (Prematurely Ended) IT (Prematurely Ended) PL (Prematurely Ended) PT (Prematurely Ended) ES (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 376  377  378  379  380  381  382  383  384  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue Jul 22 08:56:17 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA